Coherus BioSciences Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
CHRS$0.82+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibit Index
INDEX TO EXHIBITS
| · · · · Incorporated by Reference · · | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ExhibitNumber · Description · Form · Exhibit · DateFiled · FiledHerewith | ||||||||||
| 3.1 | | Amended and Restated Certificate of Incorporation. | | 8-K | | 3.1 | | 11/13/2014 | | |
| | | | | | | | | | | |
| 3.2 | | Amended and Restated Bylaws. | | 8-K | | 3.1 | | 11/18/2020 | | |
| | | | | | | | | | | |
| 4.1 | | Reference is made to exhibits 3.1 and 3.2. | | | | | | | | |
| | | | | | | | | | | |
| 4.2 | | Form of Common Stock Certificate. | | S-1/A | | 4.2 | | 10/24/2014 | | |
| | | | | | | | | | | |
| 4.3 | | Indenture, dated as of April 17, 2020, between Coherus Biosciences, Inc. and U.S. Bank National Association, as Trustee. | | 8-K | | 4.1 | | 4/17/2020 | | |
| | | | | | | | | | | |
| 4.4 | | Form of certificate representing the 1.5% Convertible Senior Subordinated Notes due 2026. | | 8-K | | 4.2 | | 4/17/2020 | | |
| | | | | | | | | | | |
| 4.5 | | Notice of Successor Trustee to Indenture dated February 7, 2022. | | 10-Q | | 4.5 | | 5/5/2022 | | |
| | | | | | | | | | | |
| 10.1†† | | Consent, Partial Release and Third Amendment to Loan Agreement dated as of February 5, 2024 among Coherus BioSciences, Inc., Biopharma Credit PLC, BPCR Limited Partnership and Biopharma Credit Investments V (MASTER) LP | | 8-K | | 10.1 | | 2/5/2024 | | |
| | | | | | | | | | | |
| 10.2†† | | Amendment No. 2 to the Exclusive License and Commercialization Agreement, as amended, as of March 13, 2024, by and between Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. | | | | | | | | X |
| | | | | | | | | | | |
| 31.1 | | Certification of Principal Executive Officer Required under Securities Exchange Act Rule 13a-14(a) and 15d-14(a). | | | | | | | | X |
| | | | | | | | | | | |
| 31.2 | | Certification of Principal Financial Officer under Securities Exchange Act Rule 13a-14(a) and 15d-14(a). | | | | | | | | X |
| | | | | | | | | | | |
| 32.1 | | Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350 and Securities Exchange Act Rule 13a-14(b). | | | | | | | | X |
| | | | | | | | | | | |
| | | | | Incorporated by Reference | | | ||||
| ExhibitNumber | Description | Form | Exhibit | DateFiled | FiledHerewith | |||||
| 101 | | The following materials from Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 formatted in iXBRL (Inline eXtensible Business Reporting Language) includes: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Loss, (iv) Condensed Consolidated Statements of Stockholders’ Deficit, (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements. | | | | | | | | X |
| 104 | | Cover page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101). | | | | | | | | X |
| | |
|---|---|
| †† | Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment or pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Additionally, schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Item 601(a)(5). |
| | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.